Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Susana Otero-Romero, Adrián Sánchez-Montalvá & Angela Vidal-Jordana. (2021) Assessing and mitigating risk of infection in patients with multiple sclerosis on disease modifying treatment. Expert Review of Clinical Immunology 17:3, pages 285-300.
Read now
Read now
Clara G. Chisari, Simona Toscano, Emanuele D’Amico, Salvatore Lo Fermo, Aurora Zanghì, Sebastiano Arena, Mario Zappia & Francesco Patti. (2019) An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety 18:10, pages 925-948.
Read now
Read now
Margaret Haugh, Viviane Gresset-Bourgeois, Bérengère Macabeo, Anne Woods & Sandrine I. Samson. (2017) A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries. Expert Review of Vaccines 16:6, pages 545-564.
Read now
Read now
Articles from other publishers (45)
Susana Otero‐Romero, Christine Lebrun‐Frénay, Saúl Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja‐Guevara, Aksel Siva, Sandra Vukusic & Mar Tintoré. (2023) European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. European Journal of Neurology 30:8, pages 2144-2176.
Crossref
Crossref
Esther S. FrischDarius HäuslerMartin S. Weber. (2023) Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation 10:4.
Crossref
Crossref
Susana Otero-Romero, Christine Lebrun-Frénay, Saúl Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic & Mar Tintoré. (2023) ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Multiple Sclerosis Journal 29:8, pages 904-925.
Crossref
Crossref
Nuray Bilge, Fatma Kesmez Can & Recep Yevgi. (2022) Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy. Acta Neurologica Belgica.
Crossref
Crossref
Enoch Kim, Alyssa Haag, Jackie Nguyen, Marc M. Kesselman & Michelle Demory Beckler. (2022) Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity. Multiple Sclerosis and Related Disorders 67, pages 104172.
Crossref
Crossref
Lil Meyer-Arndt, Julian Braun, Florent Fauchere, Kanika Vanshylla, Lucie Loyal, Larissa Henze, Beate Kruse, Manuela Dingeldey, Karsten Jürchott, Maike Mangold, Ardit Maraj, Andre Braginets, Chotima Böttcher, Andreas Nitsche, Kathrin de la Rosa, Christoph Ratswohl, Birgit Sawitzki, Pavlo Holenya, Ulf Reimer, Leif E Sander, Florian Klein, Friedemann Paul, Judith Bellmann-Strobl, Andreas Thiel & Claudia Giesecke-Thiel. (2022) SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod. Journal of Neurology, Neurosurgery & Psychiatry 93:9, pages 960-971.
Crossref
Crossref
Xi Wu, Lu Wang, Lu Shen & Kefu Tang. (2022) Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis. eBioMedicine 81, pages 104102.
Crossref
Crossref
Alexander Winkelmann, Micha Loebermann, Michael Barnett, Hans-Peter Hartung & Uwe K. Zettl. (2022) Vaccination and immunotherapies in neuroimmunological diseases. Nature Reviews Neurology 18:5, pages 289-306.
Crossref
Crossref
Nik Krajnc, Gabriel Bsteh, Thomas Berger, Jan Mares & Hans-Peter Hartung. (2022) Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics 19:3, pages 753-773.
Crossref
Crossref
Marco Iannetta, Doriana Landi, Gaia Cola, Laura Campogiani, Vincenzo Malagnino, Elisabetta Teti, Luigi Coppola, Andrea Di Lorenzo, Daniela Fraboni, Francesco Buccisano, Sandro Grelli, Marcello Mozzani, Maria Antonella Zingaropoli, Maria Rosa Ciardi, Roberto Nisini, Sergio Bernardini, Massimo Andreoni, Girolama Alessandra Marfia & Loredana Sarmati. (2022) B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications. Frontiers in Immunology 12.
Crossref
Crossref
Ashlesha Sonpar. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
25
48
.
Simona Toscano, Clara G. Chisari & Francesco Patti. (2021) Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. Neurology and Therapy 10:2, pages 627-649.
Crossref
Crossref
Tobias Monschein, Tobias Zrzavy, Micha Löbermann, Alexander Winkelmann, Thomas Berger, Paulus Rommer, Hans-Peter Hartung & Uwe K. Zettl. (2021) Die Corona-Pandemie und Multiple Sklerose: Impfungen und deren Implikationen für Patienten – Teil 2: ImpfstofftechnologienThe corona pandemic and multiple sclerosis: vaccinations and their implications for patients—Part 2: vaccine technologies. Der Nervenarzt 92:12, pages 1283-1292.
Crossref
Crossref
Tobias Zrzavy, Isabella Wimmer, Paulus S. Rommer & Thomas Berger. (2020) Immunology of COVID‐19 and disease‐modifying therapies: The good, the bad and the unknown. European Journal of Neurology 28:10, pages 3503-3516.
Crossref
Crossref
Anne‐Marie Landtblom, Shala G. Berntsson, Inger Boström & Ellen Iacobaeus. (2021) Multiple sclerosis and COVID‐19: The Swedish experience. Acta Neurologica Scandinavica 144:3, pages 229-235.
Crossref
Crossref
Marc Pawlitzki & Sven G. Meuth. (2021) Immunmodulatorische Therapien bei Multipler Sklerose in der Pandemie. InFo Neurologie + Psychiatrie 23:7-8, pages 38-47.
Crossref
Crossref
Hannah Kelly, Brent Sokola & Hesham Abboud. (2021) Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients. Journal of Neuroimmunology 356, pages 577599.
Crossref
Crossref
Patricia K. Coyle, Anne Gocke, Megan Vignos & Scott D. Newsome. (2021) Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Advances in Therapy 38:7, pages 3550-3588.
Crossref
Crossref
Tyler Ellis Smith & Ilya Kister. (2021) Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Current Neurology and Neuroscience Reports 21:7.
Crossref
Crossref
Christina Woopen, Katharina Schleußner, Katja Akgün & Tjalf Ziemssen. (2021) Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Frontiers in Immunology 12.
Crossref
Crossref
Susana Otero-Romero, Alberto Ascherio & Christine Lebrun-Frénay. (2021) Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Current Opinion in Neurology 34:3, pages 322-328.
Crossref
Crossref
Cassie Nesbitt, Louise Rath, Michael Zhong, Allen C Cheng, Helmut Butzkueven, Robb Wesselingh, Olga Skibina, Mastura Monif, Wei Yeh, Julia ML Brotherton, Stephen Reddel & Anneke Van Der Walt. (2021) Vaccinations in patients with multiple sclerosis: review and recommendations. Medical Journal of Australia 214:8, pages 350.
Crossref
Crossref
Shani Witman Tsur, Eli Adrian Zaher, Meydan Tsur, Karolina Kania & Alicja Kalinowska-Łyszczarz. (2021) Current Immunological and Clinical Perspective on Vaccinations in Multiple Sclerosis Patients: Are They Safe after All?. International Journal of Molecular Sciences 22:8, pages 3859.
Crossref
Crossref
Agostino Riva, Valeria Barcella, Simone V Benatti, Marco Capobianco, Ruggero Capra, Paola Cinque, Giancarlo Comi, Maria Michela Fasolo, Fabio Franzetti, Massimo Galli, Simonetta Gerevini, Luca Meroni, Massimo Origoni, Luca Prosperini, Massimo Puoti, Cristina Scarpazza, Carla Tortorella, Mauro Zaffaroni & Lucia Moiola. (2020) Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. Multiple Sclerosis Journal 27:3, pages 347-359.
Crossref
Crossref
Jackie Nguyen, Patrick Hardigan, Marc M. Kesselman & Michelle Demory Beckler. (2021) Immunogenicity of The Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis. Multiple Sclerosis and Related Disorders 48, pages 102698.
Crossref
Crossref
Rocco Capuano, Giovanna Donnarumma, Alvino Bisecco, Elena Grimaldi, Miriana Conte, Alessandro d’Ambrosio, Federica Matrone, Mario Risi, Riccardo Maria Borgo, Manuela Altieri, Federica Giuliano, Nicola Coppola, Massimiliano Galdiero, Gioacchino Tedeschi & Antonio Gallo. (2021) Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab. Therapeutic Advances in Neurological Disorders 14, pages 175628642110381.
Crossref
Crossref
Andrés G. Barboza, Vladimiro Sinay, Berenice Anabel Silva, Juan I. Rojas, María Célica Ysrraelit, Edgar Carnero Contentti, Laura Negrotto, Darío Tavolini, Norma Deri, Santiago Tizio, María Inés Gaitán, Geraldine Luetic, Liliana Patrucco, Alejandra D. Martínez, Marcela Parada Marcilla, Javier Hryb, Ricardo Alonso, Santiago Bestoso, Lorena M. Cabrera, Edgardo Cristiano, Miguel Jacobo, Susana Liwacki, Pablo A. Lopez, Carolina Mainella, María Laura Menichini, Jimena Miguez, Fatima Pagani Cassara, Celia Pérez, Raúl Piedrabuena, Roberto Rotta Escalante, Judith Steinberg, Veronica Analia Tkachuk, Carlos Alejandro Vrech & Gisela Zanga. (2021) Guías de práctica para indicación y contraindicaciones de vacunación de pacientes con esclerosis múltiple. Neurología Argentina 13:1, pages 24-36.
Crossref
Crossref
John Robert Ciotti, Manouela V. Valtcheva & Anne Haney Cross. (2020) Effects of MS disease-modifying therapies on responses to vaccinations: A review.. Multiple Sclerosis and Related Disorders 45, pages 102439.
Crossref
Crossref
Crystal Zheng, Indrani Kar, Claire Kaori Chen, Crystal Sau, Sophia Woodson, Alessandro Serra & Hesham Abboud. (2020) Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs 34:9, pages 879-896.
Crossref
Crossref
David Baker, Sandra Amor, Angray S. Kang, Klaus Schmierer & Gavin Giovannoni. (2020) The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Multiple Sclerosis and Related Disorders 43, pages 102174.
Crossref
Crossref
Marc Pawlitzki, Uwe K. Zettl, Tobias Ruck, Leoni Rolfes, Hans-Peter Hartung & Sven G. Meuth. (2020) Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-PandemieRisks and possibilities of immunotherapy in times of the coronavirus 2019 pandemic. DGNeurologie 3:4, pages 285-297.
Crossref
Crossref
C. Lebrun, S. Vukusic, V. Abadie, C. Achour, F. Ader, H. Alchaar, A. Alkhedr, F. Andreux, G. Androdias, R. Arjmand, B. Audoin, D. Audry, D. Aufauvre, C. Autreaux, X. Ayrignac, M. Bailbe, M. Benazet, C. Bensa, D. Bensmail, E. Berger, P. Bernady, Y. Bertagna, D. Biotti, A. Blanchard-Dauphin, J. Bonenfant, M. Bonnan, B. Bonnemain, F. Borgel, E. Botelho-Nevers, S. Boucly, B. Bourre, C. Boutière, P. Branger, D. Brassat, S. Bresch, V. Breuil, B. Brochet, H. Brugeilles, P. Bugnon, P. Cabre, J.-P. Camdessanché, C. Carra-Dalière, O. Casez, J.-M. Chamouard, B. Chassande, P. Chataignier, M. Chbicheb, A. Chenet, J. Ciron, P. Clavelou, M. Cohen, R. Colamarino, N. Collongues, I. Coman, P.-R. Corail, S. Courtois, M. Coustans, A. Creange, E. Creisson, N. Daluzeau, C. Davenas, J. De Seze, M. Debouverie, R. Depaz, N. Derache, L. Divio, X. Douay, C. Dulau, F. Durand-Dubief, G. Edan, Z. Elias, O. Fagniez, M. Faucher, J.-M. Faucheux, M. Fournier, A. Gagneux-Brunon, P. Gaida, P. Galli, P. Gallien, J. Gaudelus, D. Gault, A. Gayou, M. Genevray, A. Gentil, J. Gere, L. Gignoux, M. Giroux, P. Givron, O. Gout, J. Grimaud, A.-M. Guennoc, N. Hadhoum, P. Hautecoeur, O. Heinzlef, M. Jaeger, S. Jeannin, L. Kremer, A. Kwiatkowski, P. Labauge, C. Labeyrie, S. Lachaud, I. Laffont, C. Lanctin-Garcia, J. Lannoy, L. Lanotte, D. Laplaud, D. Latombe, M. Lauxerois, E. Le Page, C. Lebrun-Frenay, P. Lejeune, P. Lejoyeux, B. Lemonnier, E. Leray, C.-M. Loche, C. Louapre, C. Lubetzki, A. Maarouf, B. Mada, L. Magy, E. Maillart, E. Manchon, R. Marignier, P. Marque, G. Mathey, A. Maurousset, C. Mekies, M. Merienne, L. Michel, A.-M. Milor, X. Moisset, A. Montcuquet, T. Moreau, N. Morel, M. Moussa, J.-P. Naudillon, M. Normand, P. Olive, J.-C. Ouallet, O. Outteryck, C. Pacault, C. Papeix, I. Patry, D. Peaureaux, J. Pelletier, B. Pichon, S. Pittion, E. Planque, M.-C. Pouget, V. Pourcher, C. Radot, I. Robert, F. Rocher, A. Ruet, A. Ruet, C. Saint-Val, J.-Y. Salle, A. Salmon, E. Sartori, S. Schaeffer, B. Stankhof, F. Taithe, E. Thouvenot, C. Tizon, A. Tourbah, P. Tourniaire, M. Vaillant, P. Vermersch, S. Vidil, A. Wahab, M.-H. Warter, S. Wiertlewski, B. Wiplosz, B. Wittwer, C. Zaenker & H. Zephir. (2019) Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society. Revue Neurologique 175:6, pages 341-357.
Crossref
Crossref
Christine Lebrun & Sandra Vukusic. (2019) Immunization and multiple sclerosis: Recommendations from the French multiple sclerosis society. Multiple Sclerosis and Related Disorders 31, pages 173-188.
Crossref
Crossref
Norbert Wagner, Frauke Assmus, Gabriele Arendt, Erika Baum, Ulrich Baumann, Christian Bogdan, Gerd Burchard, Dirk Föll, Edeltraut Garbe, Jane Hecht, Ulf Müller-Ladner, Tim Niehues, Klaus Überla, Sabine Vygen-Bonnet, Thomas Weinke, Miriam Wiese-Posselt, Michael Wojcinski & Fred Zepp. (2019) Impfen bei Immundefizienz. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 62:4, pages 494-515.
Crossref
Crossref
Edward J. FoxGuy J. BuckleBarry SingerVibhuti SinghAaron Boster. (2019) Lymphopenia and DMTs for relapsing forms of MS. Neurology Clinical Practice 9:1, pages 53-63.
Crossref
Crossref
Christoph Metze, Alexander Winkelmann, Micha Loebermann, Michael Hecker, Brunhilde Schweiger, Emil Christian Reisinger & Uwe Klaus Zettl. (2019) Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies. CNS Neuroscience & Therapeutics 25:2, pages 245-254.
Crossref
Crossref
H. K. Olberg, G. E. Eide, R. J. Cox, Å. Jul‐Larsen, S. L. Lartey, C. A. Vedeler & K.‐M. Myhr. (2018) Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy. European Journal of Neurology 25:3, pages 527-534.
Crossref
Crossref
Lahar Mehta, Kimberly Umans, Gulden Ozen, Randy R. Robinson & Jacob Elkins. (2017) Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta. International Journal of MS Care 19:3, pages 141-147.
Crossref
Crossref
L.P. Kotra & J. Park. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
439
473
.
Eric M. L. Williamson, Salim Chahin & Joseph R. Berger. (2016) Vaccines in Multiple Sclerosis. Current Neurology and Neuroscience Reports 16:4.
Crossref
Crossref
Beuy Joob & Viroj Wiwanitkit. (2014) Immunotherapies and influenza vaccination. Multiple Sclerosis Journal 20:13, pages 1794-1794.
Crossref
Crossref
Paolo Pellegrino, Carla Carnovale, Valentina Perrone, Marco Pozzi, Stefania Antoniazzi, Sonia Radice & Emilio Clementi. (2014) Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. Vaccine 32:37, pages 4730-4735.
Crossref
Crossref
Henning K Olberg, Rebecca J Cox, Jane K Nostbakken, Jan H Aarseth, Christian A Vedeler & Kjell-Morten Myhr. (2014) Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study. Multiple Sclerosis Journal 20:8, pages 1074-1080.
Crossref
Crossref
Michael Kaufman, Gabriel Pardo, Howard Rossman, Marianne T. Sweetser, Fiona Forrestal & Petra Duda. (2014) Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis. Journal of the Neurological Sciences 341:1-2, pages 22-27.
Crossref
Crossref
O. Outteryck, J.C. Ongagna, B. Brochet, L. Rumbach, C. Lebrun-Frenay, M. Debouverie, H. Zéphir, J.C. Ouallet, E. Berger, M. Cohen, S. Pittion, D. Laplaud, S. Wiertlewski, P. Cabre, J. Pelletier, A. Rico, G. Defer, N. Derache, W. Camu, E. Thouvenot, T. Moreau, A. Fromont, A. Tourbah, P. Labauge, G. Castelnovo, P. Clavelou, O. Casez, P. Hautecoeur, C. Papeix, C. Lubetzki, B. Fontaine, N. Couturier, N. Bohossian, M. Clanet, P. Vermersch, J. de Sèze & D. Brassat. (2014) A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. European Journal of Neurology 21:1, pages 40-48.
Crossref
Crossref